Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Internet Claims Regarding SARS Prevention Provoke Warning Letters

This article was originally published in The Gray Sheet

Executive Summary

Eight manufacturers and distributors will receive 1warning letters, following a coordinated effort by the Federal Trade Commission, the FDA and the Ontario Ministry of Consumer and Business Services to "surf" the Internet for false and misleading claims related to Severe Acute Respiratory Syndrome

You may also be interested in...



Serious Disease Genetic Testing Claims More Likely To Prompt FTC Action

The Federal Trade Commission's limited oversight of regional laboratories and genetic test promotional claims for non-life-threatening diseases is eliciting concern from the HHS Secretary's Advisory Committee on Genetics, Health & Society

Serious Disease Genetic Testing Claims More Likely To Prompt FTC Action

The Federal Trade Commission's limited oversight of regional laboratories and genetic test promotional claims for non-life-threatening diseases is eliciting concern from the HHS Secretary's Advisory Committee on Genetics, Health & Society

CDRH More Reliant On SEC, FTC For Ad/Promotion Vigilance Under Policy Shift

The Center for Devices & Radiological Health increasingly is looking to other federal agencies to help regulate medical device advertising and promotion as it scales back its own claim enforcement activities

Latest Headlines
See All
UsernamePublicRestriction

Register

MT018363

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel